Abstract
Immune therapies have transformed the landscape of oncology. Immune checkpoint inhibitors are group of medications, which activate T-Cells to fight against cancer cells. Acute tubulointrestitial nephritis is the most common form of kidney immune-related adverse event. With more use of ICPIs, renal immune related side effects are being recognized more. Here we present a case of renal tubular acidosis with acute kidney injury in a patient with squamous cell carcinoma of the skull who was on Cemiplimab.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
